{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001072","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.186636+00:00","generated_at":"2026-06-29T18:24:58.496861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022","bullets":["Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.","Cash and equivalents $880.9M; royalty financing from BBA capped at $450M after second $125M tranche not paid.","Phase 3 wet AMD DAZZLE study on track topline data Q1 2022; enrollment in BEACON, GLEAM, GLIMMER, DAYLIGHT ongoing.","China IND approved for KSI-301 in RVO and DME; first patients expected in 2021.","Proposed INN for KSI-301 is tarcocimab tedromer; GLOW study in non-proliferative DR to start August 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001072","json":"https://secwatch.observer/filing/0000950170-21-001072.json","markdown":"https://secwatch.observer/filing/0000950170-21-001072.md","text":"https://secwatch.observer/filing/0000950170-21-001072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/0000950170-21-001072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/kod-20210809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:24:58.496861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}